NCT03014609 Cardiovascular Risk and Chronic Obstructive Pulmonary Disease
| NCT ID | NCT03014609 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Chronic Obstructive Pulmonary Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2017-01-09 |
| Primary Completion | 2029-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2017-01-09 with a primary completion date of 2029-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (CVR) in COPD patients, using multivariate analysis.
Eligibility Criteria
Inclusion Criteria: For patients with stable COPD: * Men or women aged 18 to 85 * FEV1/FVC \< 70% or proven BPCO * Patients who have given their free and informed consent in writing For patients with decompensated COPD: * Men or women aged 18 to 85 * FEV1/FVC \< 70% or proven BPCO * At the time of acute respiratory failure (ARF), when admitted to hospital: * Respiratory rate \> 25 cycles per minute * PaCO2 \> 45 mmHg * blood pH \< 7.35 * When included in the study: * pH \> 7.33 at the end of ARF, 2 days in a row, or 3 to 7 days post-D1 decompensation (admission to the hospital) * Fever \< 38.5°C * Patients who have given their free and informed consent in writing Exclusion Criteria: * Obvious evolving infection or CRP \> 100 mg/L * Cardiac decompensation considered the main cause of decompensation or chronic heart failure with LVEF \< 45% * Evolving neoplasia * On antioxidants: N-acetyl-cysteine, selenium, vit. C, vit. E * Pregnant or nursing women * Patients under tutorship or curatorship * Patients participating in a drug clinical research study * Patients not affiliated to the French social security system (or equivalent) * Patients deprived of liberty or hospitalized without consent.
Contact & Investigator
Jean-Louis PEPIN, ProfessorPHD
PRINCIPAL INVESTIGATOR
University Grenoble Hospital
Frequently Asked Questions
Who can join the NCT03014609 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03014609 currently recruiting?
Yes, NCT03014609 is actively recruiting participants. Contact the research team at JPepin@chu-grenoble.fr for enrollment information.
Where is the NCT03014609 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT03014609 clinical trial?
NCT03014609 is sponsored by University Hospital, Grenoble. The principal investigator is Jean-Louis PEPIN, ProfessorPHD at University Grenoble Hospital. The trial plans to enroll 150 participants.